Indivior Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was Negative Equity. Indivior Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was N/A.
Indivior Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was Negative Equity.
Indivior Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Indivior Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Indivior Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals ROE % Adjusted to Book Value Chart
FRA:E7P vs AMRX, KNSA, LQDA: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Indivior Pharmaceuticals (FRA:E7P) has a ROE % Adjusted to Book Value of Negative Equity% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' ROE % Adjusted to Book Value too high?
Indivior Pharmaceuticals' current ROE % Adjusted to Book Value is Negative Equity%. Overall, Indivior Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' ROE % Adjusted to Book Value compare to AMRX and KNSA?
Indivior Pharmaceuticals' ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (FRA:E7P) is currently considered Significantly Overvalued. The stock's GF Value™ is €19.18, compared to a current price of €34.60 — trading 80.4% above its estimated fair value. The current ROE % Adjusted to Book Value is Negative Equity%. Indivior Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Indivior Pharmaceuticals (FRA:E7P), the current ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of €34.60 is trading 80.4% above its estimated GF Value™ of €19.18.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:E7P:
ROE % Adjusted to Book Value: Negative Equity%
GF Value™: €19.18 vs. price of €34.60 (80.4% above fair value)
No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
56GF Score
Get the complete analysis for FRA:E7P
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E7P has been successfully added to your 
